Several drugs acting on the orexin system are under development, either orexin agonists for the treatment of conditions such as narcolepsy, or orexin antagonists for insomnia. No non-peptide agonists are yet available, although synthetic Orexin-A polypeptide has been made available as a nasal spray and tested on monkeys. Several non-peptide antagonists are in development however; SB-649,868 is under development by GlaxoSmithKline for sleep disorders and is a non-selective orexin receptor antagonist. Another OX1 and OX2 receptor antagonist (ACT-078573, almorexant) is a similar compound under development for primary insomnia by Actelion. A third entry is Merck's MK-4305.
Most ligands acting on the orexin system so far are polypeptides modified from the endogenous agonists Orexin-A and Orexin-B, however there are some subtype-selective non-peptide antagonists available for research purposes.
- SB-334,867 - selective OX1 antagonist
- SB-408,124 - selective OX1 antagonist
- TCS-OX2-29 - selective OX2 antagonist
- EMPA(drug) (N-Ethyl-2--N-pyridin-3-ylmethyl-acetamide) - selective OX2 antagonist
Read more about this topic: Orexin
Other articles related to "selective, ligands, selective ligands":
... He offers the selective theory as being consistent with the postulate of objectivity and allowing for epistemological coherence ... Cooperative and antagonistic interactions of ligands are indirect ligands interact with the protein not with other ligands ... subunits) and each protomer has a receptor for each of the ligands ...
... p, a, d, s), sysi/epon, spvo proc (eval/thrp), drug (N5A/5B/5C/6A/6B/6D) Adrenergics Receptor ligands α1 Agonists 5-FNE 6-FNE Amidephrine Anisodamine ...
... IC50 of 1.5 μM, highly selective over SIRT2 and SIRT3 3′-Phenethyloxy-2-anilinobenzamide (33i) IC50 of 0.57 μM ...
Famous quotes containing the word selective:
“The selective memory isnt selective enough.”
—Blake Morrison (b. 1950)